About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker MRNA · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Nov 13, 2026A Study of Updated mRNA Seasonal Influenza Vaccines
NCT07884175 · Seasonal Influenza
mRNA-1010, Licensed High-Dose Seasonal Influenza Vaccine
MRNA
ModernaTX, Inc.
Phase 4Recruiting
was not yet recruiting
200Dec 7, 2026Registry ↗
Nov 9, 2026A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 in Participants ≥6…
NCT07808697 · SARS-CoV-2
mRNA-1283, mRNA-1273
MRNA
ModernaTX, Inc.
Phase 2Recruiting
was not yet recruiting
300Aug 30, 2029Registry ↗
Nov 5, 2026A Study to Investigate the Safety, Reactogenicity, and Immunogenicity of a Preventative Vaccine for…
NCT07919210 · Marburg Virus Disease (MVD)
mRNA-1519, Placebo
MRNA
ModernaTX, Inc.
Phase 1Not yet recruiting64Apr 14, 2028Registry ↗
Nov 5, 2026A Study to Investigate the Safety and Immunogenicity of mRNA-1469 in African Participants 1 to 65 Y…
NCT07919197 · Ebola-Bundibugyo Virus Disease (Ebola-BDBV)
mRNA-1469, Placebo
MRNA
ModernaTX, Inc.
Phase 1Not yet recruiting224Feb 1, 2028Registry ↗
Nov 5, 2026A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Children
NCT07870330 · Seasonal Influenza
mRNA-1010, Fluarix Trivalent
MRNA
ModernaTX, Inc.
Phase 1Recruiting96Dec 7, 2027Registry ↗
Nov 4, 2026A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Formulatio…
NCT07863635 · SARS-CoV-2
mRNA-1273, mRNA-1283
MRNA
ModernaTX, Inc.
Phase 4Recruiting600Dec 11, 2026Registry ↗
Nov 4, 2026A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy…
NCT05831111 · Epstein-Barr Virus Infection
mRNA-1195.1, mRNA-1195.2
MRNA
ModernaTX, Inc.
Phase 1Completed
was active, not recruiting
482Oct 14, 2026Registry ↗
Oct 23, 2026Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prev…
NCT05992935 · Norovirus Acute Gastroenteritis
mRNA-1403, mRNA-1405
MRNA
ModernaTX, Inc.
Phase 1/2Completed1,407Oct 7, 2026Registry ↗
Oct 13, 2026A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in P…
NCT06880549 · Advanced Solid Tumors
mRNA-4106, Pembrolizumab
MRNA
ModernaTX, Inc.
Phase 1Recruiting42Aug 3, 2027Registry ↗
Oct 8, 2026A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes of…
NCT06508320 · Influenza, SARS-CoV-2
mRNA-1083
MRNA
ModernaTX, Inc.
Phase 2Completed931Sep 25, 2025Registry ↗
Sep 29, 2026A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Vi…
NCT05127434 · Respiratory Syncytial Virus
Placebo, mRNA-1345
MRNA
ModernaTX, Inc.
Phase 2/3Completed36,814Jul 28, 2025Registry ↗
Sep 28, 2026A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Yea…
NCT07266558 · SARS-CoV-2
mRNA-1273, mRNA-1283
MRNA
ModernaTX, Inc.
Phase 4Active, not recruiting30,000Jun 16, 2027Registry ↗
Sep 24, 2026A Study to Investigate the Safety, Reactogenicity, and Immunogenicity of mRNA-1469 Vaccine to Preve…
NCT07737717 · Ebola-Bundibugyo Virus Disease (Ebola-BDBV)
mRNA-1469, Placebo
MRNA
ModernaTX, Inc.
Phase 1Active, not recruiting84Sep 30, 2027Registry ↗
Sep 23, 2026A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
NCT07116616 · Relapsed or Refractory Multiple Myeloma
mRNA-2808
MRNA
ModernaTX, Inc.
Phase 1/2Recruiting190Jun 17, 2030Registry ↗
Sep 16, 2026A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age
NCT06602024 · Seasonal Influenza
mRNA-1010, Fluarix®
MRNA
ModernaTX, Inc.
Phase 3Completed40,805Aug 21, 2025Registry ↗
Sep 15, 2026A Study to Investigate Safety and Tolerability of mRNA-0184 Administered Subcutaneously in Healthy…
NCT06655870 · Healthy Participants
mRNA-0184
MRNA
ModernaTX, Inc.
Phase 1Recruiting42Dec 16, 2026Registry ↗
Sep 8, 2026An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembroli…
NCT03897881 · Melanoma
mRNA-4157, Pembrolizumab
MRNA
ModernaTX, Inc.
Phase 2Active, not recruiting267Nov 21, 2032Registry ↗
Sep 3, 2026Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With…
NCT03313778 · Solid Tumors
mRNA-4157, Pembrolizumab
MRNA
ModernaTX, Inc.
Phase 1Active, not recruiting161Nov 21, 2027Registry ↗
Aug 20, 2026A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syn…
NCT06067230 · Respiratory Syncytial Virus
mRNA-1345
MRNA
ModernaTX, Inc.
Phase 3Completed1,153Jul 24, 2026Registry ↗
Aug 19, 2026A Study to Investigate Safety, Reactogenicity, and Immunogenicity of mRNA-1365 (Profile 2) in Older…
NCT07764237 · Respiratory Syncytial Virus (RSV), Human Metapneuomovirus (…
mRNA-1365 (Profile 2), mRNA-1345 (Profile 1)
MRNA
ModernaTX, Inc.
Phase 1Recruiting375Jul 20, 2027Registry ↗
Aug 18, 2026A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Y…
NCT06097299 · Respiratory Syncytial Virus
mRNA-1345, Placebo
MRNA
ModernaTX, Inc.
Phase 2Completed349Jun 27, 2025Registry ↗
Aug 11, 2026A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults
NCT07496450 · Influenza
mRNA-1018-H5, Placebo
MRNA
ModernaTX, Inc.
Phase 3Active, not recruiting4,050Jan 28, 2027Registry ↗
Aug 10, 2026A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vac…
NCT05683457 · Cytomegalovirus Infection
mRNA-1647, Placebo
MRNA
ModernaTX, Inc.
Phase 2Active, not recruiting84Mar 6, 2027Registry ↗
Aug 5, 2026A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ≥…
NCT05701800 · Herpes Zoster
mRNA-1468, Placebo
MRNA
ModernaTX, Inc.
Phase 1Terminated659Dec 31, 2025Registry ↗
Aug 3, 2026A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1982 to Prevent Lyme Dis…
NCT07561294 · Lyme Disease
mRNA-1982, Placebo
MRNA
ModernaTX, Inc.
Phase 2Active, not recruiting366Nov 9, 2028Registry ↗
Jul 30, 2026A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease i…
NCT05975099 · Lyme Disease
mRNA-1975, mRNA-1982
MRNA
ModernaTX, Inc.
Phase 1/2Completed807May 30, 2025Registry ↗
Jul 14, 2026Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Partici…
NCT05533697 · Advanced Solid Tumors
mRNA-4359, Pembrolizumab
MRNA
ModernaTX, Inc.
Phase 1/2Recruiting361Feb 18, 2032Registry ↗
Jul 7, 2026A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Variant-containing Formulat…
NCT07089706 · COVID-19
mRNA-1283.251 Variant-containing Formulation
MRNA
ModernaTX, Inc.
Phase 4Completed832Jun 16, 2026Registry ↗
Jun 26, 2026A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5…
NCT05743881 · Respiratory Syncytial Virus, Human Metapneumovirus
mRNA-1345, mRNA-1365
MRNA
ModernaTX, Inc.
Phase 1Active, not recruiting186Aug 31, 2029Registry ↗
Jun 15, 2026A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo i…
NCT06735248 · Multiple Sclerosis
mRNA-1195, Placebo
MRNA
ModernaTX, Inc.
Phase 2Recruiting180Jan 8, 2029Registry ↗
Jun 10, 2026A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus in Pregnant Women and in Infants…
NCT06143046 · Respiratory Syncytial Virus
mRNA-1345, Placebo
MRNA
ModernaTX, Inc.
Phase 2Completed360May 25, 2026Registry ↗
Jun 4, 2026A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Parti…
NCT05575492 · Cytomegalovirus
mRNA-1647, Placebo
MRNA
ModernaTX, Inc.
Phase 1/2Completed873May 12, 2026Registry ↗
May 13, 2026A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for th…
NCT06592794 · Acute Gastroenteritis, Norovirus Acute Gastroenteritis
mRNA-1403, Placebo
MRNA
ModernaTX, Inc.
Phase 3Active, not recruiting37,864Feb 15, 2027Registry ↗
May 8, 2026A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy A…
NCT06033261 · Genital Herpes
mRNA-1608, BEXSERO
MRNA
ModernaTX, Inc.
Phase 1/2Completed303Apr 25, 2025Registry ↗
May 6, 2026A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy…
NCT05164094 · Epstein-Barr Virus Infection
mRNA-1189, Placebo
MRNA
ModernaTX, Inc.
Phase 1/2Active, not recruiting867Oct 5, 2026Registry ↗
May 6, 2026A Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of mRNA-3705 in Participants W…
NCT04899310 · Methylmalonic Acidemia
mRNA-3705, Placebo
MRNA
ModernaTX, Inc.
Phase 1/2Terminated18Apr 1, 2026Registry ↗
May 5, 2026Dose-Finding Trial to Evaluate the Safety and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-…
NCT04232280 · Cytomegalovirus Infection
mRNA-1647, Placebo
MRNA
ModernaTX, Inc.
Phase 2Completed315Jan 4, 2023Registry ↗
May 4, 2026A Study of mRNA-1345 Following a Primary Dose of a Licensed Protein Subunit Respiratory Syncytial V…
NCT07117487 · Respiratory Syncytial Virus
mRNA-1345
MRNA
ModernaTX, Inc.
Phase 3Completed507Mar 27, 2026Registry ↗
May 1, 2026A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ≥12 Years of Age t…
NCT05815498 · COVID-19
mRNA-1283.222, mRNA-1273.222
MRNA
ModernaTX, Inc.
Phase 3Completed13,553Apr 12, 2025Registry ↗
Apr 16, 2026Post-marketing Surveillance (PMS) Use-Result Surveillance With SPIKEVAX BIVALENT, SPIKEVAX X Inject…
NCT06333704 · SARS-CoV-2
SPIKEVAX Bivalent BA.1, SPIKEVAX Bivalent BA.4/5
MRNA
ModernaTX, Inc.
—Active, not recruiting4,207Mar 29, 2029Registry ↗
Mar 27, 2026A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Fo…
NCT06585241 · SARS-CoV-2
mRNA-1273 Variant-containing Formulation
MRNA
ModernaTX, Inc.
Phase 4Recruiting1,144Dec 31, 2026Registry ↗
Mar 24, 2026A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189 in Healthy Adults 18 to 30 Year…
NCT07478952 · Epstein-Barr Virus
mRNA-1189
MRNA
ModernaTX, Inc.
Phase 1Recruiting120May 15, 2027Registry ↗
Mar 23, 2026A Study to Assess the Long-term Safety and Clinical Activity of mRNA-3927 in Participants Previousl…
NCT05130437 · Propionic Acidemia
mRNA-3927
MRNA
ModernaTX, Inc.
Phase 1/2Recruiting50Dec 4, 2029Registry ↗
Mar 12, 2026A Study of Modified mRNA Vaccines in Healthy Adults
NCT05397223 · SARS-CoV-2, Seasonal Influenza
mRNA-1273, mRNA-1010
MRNA
ModernaTX, Inc.
Phase 1Completed308Feb 27, 2026Registry ↗
Feb 5, 2026A Retrospective Study to Characterize Participants With Propionic Acidemia
NCT05769621 · Propionic Acidemia
MRNA
ModernaTX, Inc.
—Recruiting60Sep 30, 2026Registry ↗
Feb 4, 2026A Study to Investigate Cardiac Troponin Levels After mRNA-1273.712 Vaccine in Participants 12 Throu…
NCT06634797 · Healthy Volunteers
mRNA-1273.712, Placebo
MRNA
ModernaTX, Inc.
Phase 4Completed1,000Jan 20, 2025Registry ↗
Feb 2, 2026A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA…
NCT04975893 · Cytomegalovirus Infection
mRNA-1647, mRNA-1647
MRNA
ModernaTX, Inc.
Phase 2Completed135Jan 19, 2026Registry ↗
Jan 22, 2026Open-Label Study of mRNA-3927 in Participants With Propionic Acidemia
NCT04159103 · Propionic Acidemia
mRNA-3927
MRNA
ModernaTX, Inc.
Phase 1/2Recruiting77Aug 31, 2027Registry ↗
Dec 30, 2025A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥50 Years of Age
NCT05330975 · Respiratory Syncytial Virus
Placebo, mRNA-1345
MRNA
ModernaTX, Inc.
Phase 3Completed3,317Nov 8, 2024Registry ↗
Dec 23, 2025A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults
NCT05827926 · SARS-CoV-2, Influenza
Influenza Vaccine 1, mRNA-1083.1
MRNA
ModernaTX, Inc.
Phase 1/2Completed1,758Dec 3, 2024Registry ↗

The newest 50 items, most recent first. Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 8:04 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances